Expression of the miR-155, miR-326 and IL-17/IL-23 axis in patients with essential hypertension ‒ a case-control study
DOI:
https://doi.org/10.15584/ejcem.2026.3.9Keywords:
hypertension, interleukin-17, interleukin-23, microRNAs, miR-155, miR-326Abstract
Introduction and aim. Essential hypertension (EH) is a major cardiovascular risk factor worldwide. The interleukin (IL)-17 and IL-23 axis is a key driver of Th17-mediated immune response; however, the involvement of microRNAs in modulating this axis in patients with essential hypertension remains poorly understood. This study aimed to evaluate expression profiles of miR-155 and miR-326 together with the serum of IL-17A and IL-23 in patients with EH.
Material and methods. This case-control study enrolled 100 participants (50 patients with essential hypertension and 50 healthy controls). The expression of miR-155 and miR-326 was determined by (RT-qPCR), whereas serum IL-17A and IL-23 concentrations were measured using (ELISA).
Results. IL-17A and IL-23 levels were significantly elevated in patients with essential hypertension compared to healthy controls (p<0.001). Additionally, miR-155 was significantly overexpressed, whereas miR-326 was significantly downregulated in patients with essential hypertension (P<0.001 for both). Exploratory receiver operating characteristic analysis showed preliminary discriminatory performance for miR-155, miR-326, IL-17A and IL-23 with AUC values of 0.988, 0.927, 0.974 and 0.946, respectively. No direct correlation between miRNA expression and cytokine levels was identified.
Conclusion. Patients with essential hypertension exhibit dysregulation of miR-155 and miR-326, IL-17A, and IL-23. Lack of significant correlations suggests that these biomarkers may reflect distinct aspects of hypertension-associated inflammation. Further prospective and longitudinal investigations are needed to validate these findings and clarify underlying mechanisms.
Downloads
References
Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57(2):132-140. doi:10.1161/HYPERTENSIONAHA.110.163576
Zhang Z, Zhao L, Zhou X, Meng X, Zhou X. Role of inflammation, immunity, and oxidative stress in hypertension: New insights and potential therapeutic targets. Front Immunol. 2023;13:1098725. doi:10.3389/fimmu.2022.1098725
Huang Y qing, Huang C, Zhang B, Feng Y. Association of circulating miR-155 expression level and inflammatory markers with white coat hypertension. J Hum Hypertens. 2020;34(5):397-403. doi:10.1038/s41371-019-0250-7
Rudemiller NP, Crowley SD. Interactions Between the Immune and the Renin–Angiotensin Systems in Hypertension. Hypertension. 2016;68(2):289-296. doi:10.1161/HYPERTENSIONAHA.116.06591
Higaki A, Mahmoud AUM, Paradis P, Schiffrin EL. Role of interleukin-23/interleukin-17 axis in T-cell-mediated actions in hypertension. Cardiovasc Res. 2021;117(5):1274-1283. doi:10.1093/cvr/cvaa257
Bloch Y, Bouchareychas L, Merceron R, et al. Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL-12Rβ1. Immunity. 2018;48(1):45-58.e6. doi:10.1016/j.immuni.2017.12.008
Davis GK, Fehrenbach DJ, Madhur MS. Interleukin 17A: Key Player in the Pathogenesis of Hypertension and a Potential Therapeutic Target. Curr Hypertens Rep. 2021;23(3):13. doi:10.1007/s11906-021-01128-7
Jung R, Lehmann A, Knopp T, et al. Antagonizing IL-17A Reduces Vascular Inflammation and Attenuates Oxidative Stress Formation but Does Not Significantly Improve Vascular Dysfunction Induced by One Week of Angiotensin II Treatment. Antioxidants (Basel). 2026;15(2):229. doi:10.3390/antiox15020229
Norlander AE, Saleh MA, Kamat NV, et al. Interleukin-17A Regulates Renal Sodium Transporters and Renal Injury in Angiotensin II-Induced Hypertension. Hypertension. 2016;68(1):167-174. doi:10.1161/HYPERTENSIONAHA.116.07493
Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55(2):500-507. doi:10.1161/HYPERTENSIONAHA.109.145094
Krebs CF, Lange S, Niemann G, et al. Deficiency of the Interleukin 17/23 Axis Accelerates Renal Injury in Mice With Deoxycorticosterone Acetate+Angiotensin II–Induced Hypertension. Hypertension. 2014;63(3):565-571. doi:10.1161/HYPERTENSIONAHA.113.02620
Ahmed EES, Ali FHA, Basry AE, El-Deeb MA. Assessment of IL23/Th17 Axis in Egyptian Patients with Grade 2 Hypertension. Egyptian Journal of Hospital Medicine. 2022;87(1):2259-2264. doi:10.21608/ejhm.2022.234293
Yao R, Ma YL, Liang W, et al. MicroRNA-155 Modulates Treg and Th17 Cells Differentiation and Th17 Cell Function by Targeting SOCS1. PLoS ONE. 2012;7(10):e46082. doi:10.1371/journal.pone.0046082
Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009;10(12):1252-1259. doi:10.1038/ni.1798
Wang J, Chen J, Chen C, Huang S, Rao X, Zhong J. Elevated Th17 and IL-23 in Hypertensive Patients with Acutly Increased Blood Pressure. Am J Immunol. 2012;8(2):27-32. doi:10.3844/ajisp.2012.27.32
Abo-Ali F, Ahmed EE, El-deeb MA, Basry AEA. Elevated IL 23 in Hypertensive Patients with Acutely Increased Blood Pressure. QJM. 2020;113(1):hcaa052.059. doi:10.1093/qjmed/hcaa052.059
Saleh MA, Norlander AE, Madhur MS. Inhibition of Interleukin-17A, But Not Interleukin-17F, Signaling Lowers Blood Pressure, and Reduces End-Organ Inflammation in Angiotensin II–Induced Hypertension. JACC: Basic to Translational Science. 2016;1(7):606-616. doi:10.1016/j.jacbts.2016.07.009
Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JAM. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res. 2007;35(Web Server issue):W71-74. doi:10.1093/nar/gkm306
Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods. 2001;25(4):402-408. doi:10.1006/meth.2001.1262
Itani HA, McMaster WG, Saleh MA, et al. Activation of human T cells in hypertension: Studies of Humanized Mice and Hypertensive Humans. Hypertension. 2016;68(1):123-132. doi:10.1161/HYPERTENSIONAHA.116.07237
Yao W, Sun Y, Wang X, Niu K. Elevated Serum Level of Interleukin 17 in a Population With Prehypertension. J Clin Hypertens (Greenwich). 2015;17(10):770-774. doi:10.1111/jch.12612
Guzik TJ, Nosalski R, Maffia P, Drummond GR. Immune and inflammatory mechanisms in hypertension. Nat Rev Cardiol. 2024;21(6):396-416. doi:10.1038/s41569-023-00964-1
Caiazzo E, Sharma M, Rezig AOM, et al. Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis. Pharmacol Res. 2024;200:107050. doi:10.1016/j.phrs.2023.107050
Kara SP, Ozkan G, Yılmaz A, Bayrakçı N, Güzel S, Geyik E. MicroRNA 21 and microRNA 155 levels in resistant hypertension, and their relationships with aldosterone. Ren Fail. 2021;43(1):676-683. doi:10.1080/0886022X.2021.1915800
Özkan G, Ulusoy Ş, Geyik E, Erdem Y. Down-regulation of miRNA 145 and up-regulation of miRNA 4516 may be associated with primary hypertension. J Clin Hypertens (Greenwich). 2019;21(11):1724-1731. doi:10.1111/jch.13704
Nafari M, Asri N, Rostami-Nejad M, et al. Elevated interleukin-17A levels despite reduced microRNA-326 gene expression in celiac disease patients under gluten-free diet. Rom J Intern Med. 2022;60(3):166-172. doi:10.2478/rjim-2022-0011
Huang J, Xu X, Yang J. miRNAs Alter T Helper 17 Cell Fate in the Pathogenesis of Autoimmune Diseases. Front Immunol. 2021;12:593473. doi:10.3389/fimmu.2021.593473
Cerda A, Amaral AA, de Oliveira R, et al. Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients. Int J Mol Sci. 2021;22(3):1468. doi:10.3390/ijms22031468
Thomou T, Mori MA, Dreyfuss JM, et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature. 2017;542(7642):450-455. doi:10.1038/nature21365
Vega-Cárdenas M, Uresti-Rivera EE, Cortés-García JD, et al. Increased levels of adipose tissue-resident Th17 cells in obesity associated with miR-326. Immunology Letters. 2019;211:60-67. doi:10.1016/j.imlet.2019.05.010
Chehimi M, Vidal H, Eljaafari A. Pathogenic Role of IL-17-Producing Immune Cells in Obesity, and Related Inflammatory Diseases. J Clin Med. 2017;6(7):68. doi:10.3390/jcm6070068
Zhang S, Gang X, Yang S, et al. The Alterations in and the Role of the Th17/Treg Balance in Metabolic Diseases. Front Immunol. 2021;12:678355. doi:10.3389/fimmu.2021.678355
Kang YS. Obesity Associated Hypertension: New Insights into Mechanism. Electrolyte Blood Press. 2013;11(2):46-52. doi:10.5049/EBP.2013.11.2.46
Rakib A, Kiran S, Mandal M, Singh UP. MicroRNAs: a crossroad that connects obesity to immunity and aging. Immun Ageing. 2022;19(1):64. doi:10.1186/s12979-022-00320-w
Bryniarski P, Nazimek K, Marcinkiewicz J. Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs-Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. Int J Mol Sci. 2022;23(3):1772. doi:10.3390/ijms23031772
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
